1,354 reports of this reaction
2.1% of all ATOMOXETINE HYDROCHLORIDE reports
#6 most reported adverse reaction
SOMNOLENCE is the #6 most commonly reported adverse reaction for ATOMOXETINE HYDROCHLORIDE, manufactured by Eli Lilly and Company. There are 1,354 FDA adverse event reports linking ATOMOXETINE HYDROCHLORIDE to SOMNOLENCE. This represents approximately 2.1% of all 63,960 adverse event reports for this drug.
Patients taking ATOMOXETINE HYDROCHLORIDE who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is a less commonly reported adverse event for ATOMOXETINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to somnolence, the following adverse reactions have been reported for ATOMOXETINE HYDROCHLORIDE:
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 1,354 FDA reports for ATOMOXETINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 2.1% of all adverse event reports for ATOMOXETINE HYDROCHLORIDE, making it a notable side effect.
If you experience somnolence while taking ATOMOXETINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.